Clinical research blog
Explore our blog for insights into the big questions in precision medicine and clinical research.
Precision medicine marks a shift from the one-size-fits-all approach to healthcare to tailored treatments and interventions that cater to an individual's unique genetic makeup, lifestyle, and environment. While precision medicine has the potential to improve patient outcomes and speed up clinical trials, it relies on the participation of diverse and representative populations. Diversity ensures that medical insights are applicable across a wide range of individuals, preventing biassed results that may favour specific ethnic or demographic groups.
In this webinar, Patrick Short, CEO of Sano Genetics, discussed opportunities to improve clinical trial patient recruitment in decentralised clinical trials (DCT) with Joss Warren, the Vice President of Strategic Accounts at THREAD Research. Their discussion covered how DCTs are changing the clinical research landscape, and what they mean for diversity in clinical trials as well as the future of precision medicine.
Our latest insights report explores multiple sclerosis (MS), providing details on the essential aspects of MS, from its impact on the central nervous system to the varying types of the condition. We share insights on:
In this webinar, Sano co-founder and CEO Patrick Short discusses the essentials of genetics and genomics, including genetic variation, genetic testing, and more. Patrick offers a thorough overview of current discoveries and discusses how they may impact the future of clinical practice.
Rare diseases may impact a small portion of the population, yet their significance is profound. And while rare disease patient recruitment might seem similar to recruitment for more prevalent conditions, it's a puzzle of its own. Conditions affecting a fraction of the population present complex obstacles. From the intricate challenge of participant scarcity, where the rarity of these conditions presents a unique hurdle, to the multi-faceted complexities of engagement, the world of rare disease trials demands innovative strategies that reframe the way we approach research.
In recent years, it's been discovered that genetics can play a big role in developing a condition and even affect how a patient might respond to treatment. Because our genes can have such an impact on our health, genetic screening has become an important part of many clinical trials. With precision medicine research coming to the fore, how can researchers and their teams plan ahead to incorporate genetics into their enrolment planning?
Last month, our team had the pleasure of attending the European Network to Cure ALS (ENCALS) meeting, an annual gathering that brings together some of the brightest minds in the field of amyotrophic lateral sclerosis (ALS) research and treatment. Each year, the ENCALS meeting reaffirms the commitment of the scientific community to ending ALS and brings renewed hope to patients and their families. While our team enjoyed networking with attendees and catching up on the latest research in ALS, this year they were also focused on Sano’s poster presentation for an initiative we are calling Light the Way.
£330K grant awarded to support and engage patients at risk of MND/ALS, and track the psychological impact of genetic testing.
This webinar, featuring Sano Genetics team members Ross Rounsevell and George Bowley, highlights the importance of purposeful participant engagement in research studies. The discussion centres around meaningful research participant engagement, its significance in research, strategies for effective engagement, and the future developments enabling better study design.
Our latest insights report focuses on Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder with significant implications for lung and liver health. AATD arises from a deficiency of the alpha-1 antitrypsin protein, which safeguards the lungs from damage. However, with this protein in short supply, the lungs become susceptible to inflammation, potentially leading to conditions like emphysema and chronic obstructive pulmonary disease (COPD).